Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?

Johnson & Johnson will report Q4 and full-year 2025 results on Jan. 21 with Zacks consensus Q4 revenue of $24.14 billion and EPS of $2.50; full-year 2025 EPS consensus has been trimmed slightly to $10.83 (2026 to $11.46). Zacks expects Innovative Medicines sales of $15.43 billion (Darzalex $3.74B, Tremfya $1.36B, Erleada $936M, Stelara $1.36B) and MedTech sales of $8.71 billion; management reiterates a preliminary 2026 outlook of >5% revenue growth and adjusted EPS roughly $0.05 above prior consensus. The company has beaten EPS in the last four quarters and the stock is up ~48.7% Y/Y trading at a forward P/E of 19.0, but near-term risks include Stelara biosimilar entry, Medicare Part D redesign headwinds, China VBP pressure and ongoing talc litigation.

Analysis

Market structure: Biosimilar entrants (Amgen, Teva and partners) are clear near-term winners as they add supply into the immunology biologics market and will pressure JNJ’s Stelara (Zacks est. $1.36bn Q4). That supply shock will compress pricing power for JNJ’s mature biologics and shift share to lower-cost producers; MedTech headwinds in China (VBP) tighten demand there and keep margin pressure on device peers. Cross-asset: a weak print or conservative 2026 guide would widen JNJ IG credit spreads and lift defensive Treasuries; a beat plus confident 2026 guidance should compress JNJ spreads, tighten equity implied vols and strengthen USD versus CNY on growth re-rating.

Risk assessment: Tail risks include an adverse talc ruling >$5–10bn, faster-than-expected biosimilar penetration (>30% share within 12 months), or deeper Medicare Part D redesign cuts that knock 5–10% off high-margin U.S. pharma revenue. Immediate (days): Jan 21 Q4 print and any 2026 guidance revisions; short-term (weeks–3 months): market digestion of guidance and pipeline readouts; long-term (2026+) depends on commercialization of ~10 high‑potential launches (company claims up to $5bn peak each). Hidden dependency: royalty/license terms and payer contracting determine realized downside vs. headline biosimilar volumes.

Trade implications: Tactical long JNJ exposure (2–3% portfolio) ahead of Jan 21 is defendable but should be hedged — buy 45–75 day 5–7% OTM puts or use a call‑spread to cap premium. Relative value: pair long JNJ / short TEVA (equal dollar 1–2% notionals) for 3–9 months — TEVA should capture some biosimilar benefit but has weaker free cash flow and higher tail-risk. Options: buy a 45‑day debit call spread to play upside if guidance is upgraded; alternatively buy near‑term puts to protect large pre-earnings holdings.

Contrarian angles: The market may be underpricing multi-year pipeline optionality — 10 candidates × ~$5bn peak = structural upside that isn’t captured in near-term EPS drift (2026 est $11.46). Conversely, the 48% YTD rally and forward P/E ~19 vs industry 17.7 suggest part of this is already priced; mispricing window likely 1–3 trading days post‑earnings when IV collapses and fundamentals re-score. Watch for management signaling M&A or accelerated buybacks as an unexpected positive catalyst that could trigger multiple expansion.

Key Decisions for Investors

• Establish a 2–3% long position in JNJ ahead of the Jan 21 print (risk/reward favors a disciplined long given diversified cash flow). Hedge the position with a 45–75 day 5–7% OTM put sized at 25–50% of the notional long to limit downside through the print.
• Implement a pair trade: go long JNJ (1.5–2% portfolio) and short TEVA (1–1.5%), 3–9 month horizon, equal-dollar notional. Rationale: TEVA benefits from biosimilars but has weaker FCF/credit and more execution risk — this isolates JNJ’s franchise and pipeline upside.
• If directional upside is preferred, buy a 45-day call debit spread on JNJ sized to 0.5–1% portfolio (buy nearer-term ATM call, sell a higher strike 3–6% above) to limit IV cost; target 8–12% absolute stock move for exit or roll at 50% of max profit.
• If holding >3% exposure into earnings, reduce net exposure by 25–40% or buy protective puts (45–75 day, ~5–7% OTM). Exit or re-assess within 3 trading days after Jan 21 to capture post‑earnings IV collapse and reprice on guidance.
• Over 3–12 months, overweight diversified large-cap healthcare (JNJ, large pharma with sustainable pipelines) and underweight pure-play generics/distribution names; reallocate 2–4% of portfolio accordingly as biosimilar rollouts and China VBP continue to evolve.